Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR1F | P30939 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023767 | 0.87 | HTR6 (0.55) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL29208205 | 0.82 | HTR6 (0.51) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL743239 | 0.78 | HTR6 (0.64) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL16916430 | 0.78 | HTR6 (0.55) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL29686864 | 0.77 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL260867 | 0.77 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5746143 | 0.77 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL30644286 | 0.77 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL20843619 | 0.77 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL4019658 | 0.77 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080101-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2008060998-A1 | INDOLE SULFONAMIDES AS SFRP-1 MODULATORS | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | PSMG3, PSMD2, PSME1 | HTR6 3730/4885HTR1A 3794/4885HTR1D 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.